Pfizer Inc. Stock
€23.73
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Pfizer Inc. | 0.810% | -2.727% | -6.961% | -32.311% | -9.100% | -25.859% | -30.141% |
Biogen Inc. | 3.260% | 7.014% | -0.459% | -25.172% | -17.176% | -12.343% | -5.355% |
Elanco Animal Health Inc. | 2.540% | 2.041% | -15.545% | 45.687% | -8.299% | -51.646% | - |
AbbVie Inc. | -4.160% | -4.443% | -9.758% | 1.814% | 6.538% | 61.993% | 109.311% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Pfizer Inc. (NYSE: PFE) appear to be strong, showcasing a robust position in the pharmaceuticals industry. As a prominent player, Pfizer has consistently demonstrated growth in its total assets and revenue, laying the foundation for a favorable outlook on the company's performance. As we dive deeper into the financial statements, it becomes essential to analyze the pros and cons to acquire a comprehensive understanding of Pfizer's financial health and future potential.
*Pros: *
Growing Total Assets and Shareholders' Equity: The company's total assets have grown consistently over the past three years, from approximately €154.2 billion in 2020 to €181.5 billion in 2021, and reaching a notable USD 197.2 billion in 2022. Such growth indicates strong financial management and an increased capacity to generate income. Similarly, the total stockholder equity has also risen, reflecting the company's ability to create value for its shareholders.
Comments
News
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
"If you don't find a way to make money while you sleep, you will work until you die." That's a quote from billionaire investor Warren Buffett which emphasizes the importance of making your money
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe
Pfizer Declares Second-Quarter 2024 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’s common stock, payable June 14, 2024, to holders of the Common